Nektar Therapeutics
NKTRNektar Therapeutics reported a net loss of $164.1 million for FY 2025, driven by an operating loss of $140.1 million on total revenue of $55.2 million.
NASDAQ
Healthcare
Biotechnology
$77.01
+1.30(1.7%)
52W $7.36 – $76.99
AI-generated
Nektar Therapeutics reported a net loss of $164.1 million for FY 2025, driven by an operating loss of $140.1 million on total revenue of $55.2 million.
Revenue breakdown: Non Cash Royalties (43.7%), Non Cash Royalty Revenue Related To Sale Of Future Royalties (43.7%), Product (12.3%).
$1.6BMkt Cap
$55MRev TTM
-$164MNI TTM
-9.2xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 12, 2026Nektar Therapeutics reported a net loss of $164.1 million for FY 2025, driven by an operating loss of $140.1 million on total revenue of $55.2 million. The company's revenue was primarily from license, collaboration, and other sources, with no product sales. Operating expenses totaled $195.3 million, dominated by research and development ($117.3 million) and general and administrative costs ($68.7 million)....
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Non Cash Royalties43.7%($119M)
Non Cash Royalty Revenue Related To Sale Of Future Royalties43.7%($119M)
Product12.3%($34M)
License Collaboration And Other Revenue0.3%($897.0K)
Revenue by Geography
Non Us99.1%($152M)
US0.9%($1M)
Analyst View
Company Profile
CIK0000906709
ISINUS6402683063
CUSIP640268306
Phone415 482 5300
Address455 Mission Bay Boulevard South, San Francisco, CA, 94158, US
SEC EDGAR